Participate in Research

Investigational Drug in Chronic Heart Failure Patients
Protocol: STUDY00005892
Full Title
A pivotal phase 3 randomized, placebo-controlled clinical study to evaluate the efficacy and safety of the sGC stimulator vericiguat/MK-1242 in adults with chronic heart failure with reduced ejection fraction
This clinical trial is exploring the use of an investigational drug (sGC stimulator vericiguat/MK-1242) in patients with chronic heart failure. Specifically, trial doctors are interested in assessing the safety of this drug and if it works well to lower some of the risks of heart failure. All participants will be able to stay on their current heart failure medication during the 2-year trial period.
Compensation: Yes
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
1) History of chronic stable, NYHA class II to IV CHF 2) NT-proBNP 600 - 6000 3) LVEF of <40% assessed within 12 months before randomization
Age Group: Adults
Principal Investigator: JOSEPH IZZO
+1 716-898-5653
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact